血管舒缩功能异常是心力衰竭、休克的关键病理环节之一。参附注射液（SFI）已被广泛应用于治疗休克、心力衰竭等，疗效确切；SFI研究多侧重于保护心脏方面，而对血管舒缩功能的研究较少。本课题组前期研究发现SFI可通过NO途径舒张血管，且全方与主要组分的作用不同。本项目拟在此基础上，建立离体血管环实验方法，采用大鼠离体胸主动脉和肠系膜微血管模型，分别考察SFI及主要组分人参皂苷、附子生物碱对血管舒缩功能的影响，明确其调节血管活性的作用；建立血管内皮细胞模型，围绕eNOS系统，采用ELISA、Western blot、RT-PCR等方法，探讨其对NO和ET-1含量，Cav-1、eNOS、COX-1、PIG2蛋白表达，eNOS和CaM的基因表达以及eNOS的Ser1177、Thr495位点磷酸化水平的影响，揭示其作用机制；探讨SFI"组分-效应"，阐述SFI配伍的科学内涵，为临床应用提供科学依据。

Vasomotor dysfunction is one of the key pathological aspects of heart failure and shock.ShenFu injection, one of the modern Chinese medicine preparations, has been widely used in the treatment for CVD, such as shock, heart failure and so on, and has significant effect. However, the research nowadays on its pharmacological mechanism mostly focused on its cardioprotection, but which on vascular activity regulation was rarely reported. Our previous researches revealed that Shenfu injection shows a vasodilatory effect and there was a difference in this funtion between the whole injection and its main components. Based on the above, this research will target on the isolated rat thoracic aorta, mesentery microvascular and vascular endothelial cells to further study on the impact of the whole injection and its main components ginsenoside and aconite alkaloids on vasomotor function. The NO and ET-1 content, the protein expression of Cav-1, eNOS, COX-1 and PIG2, the genetic expression of eNOS and calmodulin(CAM), the phosphorylation of the eNOS in Ser1177 and Thr495 sites of vascular endothelial cells will be evaluated respectively by detection methods, such as ELISA, Western blot and RT-PCR et al. This study is aim to reveal the mechanism of their vasomotor function, illustrate the scientific connotation of compatibility in Shenfu injection and provide scientific basis for its clinical application.